EMEA-003540-PIP01-23 - paediatric investigation plan

vixarelimab
PIPHuman

Key facts

Active Substance
vixarelimab
Therapeutic area
Respiratory, thoracic and mediastinal disorders
Decision number
P/0095/2024
PIP number
EMEA-003540-PIP01-23
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of idiopathic pulmonary fibrosis
Route(s) of administration
Subcutaneous use
Contact for public enquiries

Roche Registration GmbH
E-mail: global.paediatrics@roche.com
Tel. +41 6169 79411

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date

Decision

Share this page